Table 2 Selective clinical trials of AR signaling inhibitors
From: Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Drug | Target | Condition | Status | Phase | NCT identifier |
---|---|---|---|---|---|
Degarelix | GnRHR | PCa | Completed | 3 | NCT00451958 |
Degarelix | GnRHR | PCa | Completed | 3 | NCT01071915 |
Degarelix | GnRHR | PCa | Completed | 3 | NCT02015871 |
Relugolix | GnRHR | PCa | Recruiting | 3 | NCT05050084 |
Relugolix | GnRHR | PCa | Completed | 3 | NCT03085095 |
Abarelix | GnRHR | PCa | Completed | 3 | NCT00841113 |
Leuprolide | GnRHR | PCa | Completed | 4 | NCT00220194 |
Leuprolide | GnRHR | PCa | Recruiting | 3 | NCT04914195 |
Goserelin | GnRHR | PCa | Completed | 3 | NCT00439751 |
Goserelin | GnRHR | PCa | Not yet recruiting | 4 | NCT03971110 |
Triptorelin | GnRHR | PCa | Completed | 3 | NCT01715129 |
Triptorelin | GnRHR | PCa | Completed | 3 | NCT00104741 |
Histrelin | GnRHR | Metastatic PCa | Recruiting | 2/3 | NCT04787744 |
Histrelin | GnRHR | PCa | Completed | 3 | NCT01697384 |
Buserelin | GnRHR | PCa | Completed | 3 | NCT00003653 |
Buserelin | GnRHR | PCa | Recruiting | 3 | NCT05050084 |
Enzalutamide | AR | CRPC | Completed | 3 | NCT00974311 |
Enzalutamide | AR | mCRPC | Completed | 4 | NCT02116582 |
Enzalutamide | AR | mCRPC | Completed | 4 | NCT02485691 |
Apalutamide | AR | PCa | Completed | 2 | NCT01790126 |
Apalutamide | AR | Nonmetastatic CRPC | Recruiting | 3 | NCT04108208 |
Darolutamide | AR | PCa | Not yet recruiting | 3 | NCT02799602 |
Darolutamide | AR | Nonmetastatic CRPC | Completed | 3 | NCT02200614 |
ARV-110 | AR | mCRPC | Recruiting | 1/2 | NCT03888612 |
Abiraterone | CYP17A1 | mCRPC | Completed | 3 | NCT04056754 |
Abiraterone | CYP17A1 | mCRPC | Completed | 3 | NCT00887198 |
Abiraterone | CYP17A1 | mCRPC | Completed | 3 | NCT02111577 |
Seviteronel | CYP17A1 | CRPC | Completed | 2 | NCT02445976 |
Orteronel | CYP17A1 | mCRPC | Completed | 3 | NCT01193257 |
Galeterone | CYP17A1 | CRPC | Completed | 2 | NCT01709734 |